Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sabatolimab in AML with MRD post-transplant
NCT04623216Phase 2Terminated
- Sponsor
- Novartis
- Start
- Sep 2021
- Primary completion
- Aug 2024
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 2, open-label trial of sabatolimab in acute myeloid leukemia (AML) (5 arms), sponsored by Novartis. Primary endpoints: Rate of Dose Limiting Toxicities at 8 weeks, Percentage of Adult Subjects With Absence of Hematologic Relapse Per Investigator Assessment at 24 weeks and 1 more. Started Sep 2021; status: terminated.
02
Drugs
sabatolimab
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04623216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04623216.